The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 3:29 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #54. Emergent BioSolutions Inc. Healthcare Protective Products Division from Bracco Diagnostics Inc.

Acquirer: Emergent BioSolutions Inc. (NYSE:EBS)
Acquiree: Healthcare Protective Products Division from Bracco Diagnostics Inc.
Details: Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. This acquisition, which includes the RSDL (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration (FDA) for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent's biodefense franchise into the chemical countermeasure market.

Emergent BioSolutions is a life sciences company focused on providing a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). Co. is focused on products and solutions that address the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). Co. has a product portfolio of ten marketed products (vaccines, therapeutics, and drug-device combination products).

EBS SEC Filing Email Alerts Service


Open the EBS Page at The Online Investor »

Company Name: 
Emergent BioSolutions Inc
Stock buyback: 
EBS buyback
Website: 
www.emergentbiosolutions.com
Sector: 
Biotechnology
Number of ETFs Holding EBS: 
62
Total Market Value Held by ETFs: 
$661.39M
Total Market Capitalization: 
$3.97B
% of Market Cap. Held by ETFs: 
16.66%
 

Open the EBS Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Buy (3.14 out of 4)
36th percentile
(ranked lower than approx. 64% of all stocks covered)

Analysts' Target Price:
EBS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 54 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.